Altuviiio Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to dependence on standard factor viii therapies, high bleeding episode burden, frequent infusion requirements, early recombinant factor adoption, hemophilia treatment center growth.

The growth in the forecast period can be attributed to demand for long acting therapies, expansion of prophylaxis guidelines, pediatric treatment uptake, innovation in clotting factor engineering, improved reimbursement coverage. Major trends in the forecast period include shift toward extended half-life factor therapies, reduced injection frequency in hemophilia care, improved patient adherence and quality of life, expansion of prophylactic treatment adoption, rising preference for advanced recombinant factors.

The increasing prevalence of hemophilia is expected to drive the growth of the altuviiio market in the coming years. Hemophilia is a rare inherited bleeding disorder in which blood fails to clot properly due to a deficiency or absence of clotting factors. The rising prevalence of hemophilia is attributed to improved diagnostic capabilities and advances in treatment that enhance disease detection and extend patient life expectancy. Altuviiio is used in the treatment of hemophilia A by replacing missing factor VIII, helping to control bleeding episodes while offering an extended half-life that allows for less frequent dosing. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,788 patients living with hereditary haemophilia A (HMA) in 2023-2024, an increase from 2,681 patients in 2022-2023. Therefore, the rising prevalence of hemophilia is driving the growth of the altuviiio market.

Key companies operating in the altuviiio market are increasingly focused on developing advanced therapies, including extended half-life factor replacements, to improve bleed protection, enhance patient quality of life, and reduce treatment burden. Extended half-life factor replacements are engineered clotting factors designed to remain active in the bloodstream for a significantly longer duration than conventional therapies, allowing for fewer infusions to prevent bleeding episodes. For example, in February 2023, Sanofi SA, a France-based pharmaceutical company, received FDA approval for ALTUVIIIO, a novel once-weekly therapy for hemophilia A, representing a major advancement in available treatment options. This new class of factor VIII therapy substantially improves bleed protection by maintaining normal to near-normal factor activity levels with a single weekly dose. Using innovative Fc fusion technology, ALTUVIIIO delivers a longer half-life compared to traditional treatments, leading to a notable reduction in bleeding episodes, supported by clinical trial results showing a mean annualized bleeding rate of 0.70. This approval, which followed multiple regulatory designations including Breakthrough Therapy and Fast Track, marks a significant milestone in hemophilia management and offers the potential for improved patient quality of life.

In February 2023, Sanofi SA, a France-based pharmaceutical company, entered into a partnership with Swedish Orphan Biovitrum. This collaboration is focused on the development and commercialization of innovative hemophilia therapies, including Alprolix, Elocta/Eloctate, and Altuviiio, with the goal of improving patient outcomes and expanding global access to transformative treatments for rare blood disorders. Swedish Orphan Biovitrum is a Sweden-based pharmaceutical company.

Major companies operating in the altuviiio market are Swedish Orphan Biovitrum.

North America was the largest region in the altuviiio market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the altuviiio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the altuviiio market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the altuviiio market by increasing costs related to recombinant protein manufacturing inputs, sterile packaging materials, and cold chain logistics. These effects are most visible across hospital pharmacies and specialty distribution channels. Regions such as north america and europe face moderate pricing pressure due to biologic import dependence. At the same time, tariffs are encouraging localized biologic manufacturing investments. This is supporting long-term supply security and treatment continuity.

The altuviiio market research report is one of a series of new reports that provides altuviiio market statistics, including altuviiio industry global market size, regional shares, competitors with a altuviiio market share, detailed altuviiio market segments, market trends and opportunities, and any further data you may need to thrive in the altuviiio industry. This altuviiio market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Altuviiio is the brand name for efanesoctocog alfa, an advanced therapeutic agent used to treat hemophilia A, a hereditary bleeding disorder resulting from a deficiency of clotting factor VIII. It is engineered to offer prolonged protection against bleeding, allowing for less frequent dosing than conventional factor VIII therapies and thereby enhancing patient convenience.

The primary indications for altuviiio include hemophilia A, prophylactic treatment, and on-demand therapy. Hemophilia A is a genetic condition in which blood clotting is impaired due to insufficient levels of clotting factor VIII. The product is distributed through multiple channels, including hospital pharmacies and specialty pharmacies, and is intended for various end users such as pediatric, adult, and geriatric patients.

The altuviiio market consists of sales of products including adynovate, advate, kovaltry, and jivi. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.